GlassScriptPhysician profile
Donald B Wender
NPI 1861463275
$22,111.45
in general payments reported to CMS, 2019-2025
95 companies · $2,300 in 2025
The $2,300 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,566 · 2020: $1,212 · 2021: $2,824 · 2022: $5,006 · 2023: $3,225 · 2024: $2,979 · 2025: $2,300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,543 · Education: $961.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,543.15 |
| Education | $960.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,238.82 | 2019-2025 | Enhertu, Calquence, Lynparza |
| Celgene Corporation | $1,773.39 | 2019-2025 | Pomalyst, Reblozyl |
| Ipsen Biopharmaceuticals, INC | $1,264.29 | 2019-2025 | Onivyde, Tazverik, Somatuline Depot |
| E.R. Squibb & Sons, L.L.C. | $975.16 | 2019-2025 | Opdivo, Opdualag, Reblozyl |
| Janssen Biotech, INC. | $943.25 | 2019-2025 | Carvykti, Tecvayli, Darzalex |
| Seagen INC. | $928.71 | 2019-2023 | Padcev, Tukysa, Adcetris |
| Merck Sharp & Dohme LLC | $884.51 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Novartis Pharmaceuticals Corporation | $784.06 | 2019-2025 | Kisqali, Piqray |
| Genentech USA, INC. | $718.44 | 2019-2025 | Tecentriq, Lunsumio, Gazyva |
| Genzyme Corporation | $674.97 | 2019-2024 | |
| Daiichi Sankyo INC. | $648.67 | 2020-2025 | Enhertu, Injectafer, Datroway |
| Astellas Pharma US INC | $629.33 | 2019-2025 | Padcev, Xospata, Xtandi |
| Amgen INC. | $583.17 | 2019-2023 | Vectibix, Xgeva, Nplate |
| Pfizer INC. | $555.99 | 2019-2025 | |
| Abbvie INC. | $511.58 | 2019-2025 |
Show all 90 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $443.97 | 2019-2024 | Verzenio, Jaypirca, Retevmo |
| Incyte Corporation | $440.78 | 2019-2025 | Jakafi, Pemazyre, Monjuvi |
| Eisai INC. | $406.93 | 2020-2025 | |
| Servier Pharmaceuticals LLC | $381.23 | 2021-2025 | |
| Exelixis INC. | $341.02 | 2019-2025 | Cabometyx |
| Gilead Sciences, INC. | $282.08 | 2019-2025 | Trodelvy |
| Sanofi-Aventis U.S. LLC | $253.98 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $249.68 | 2019-2025 | Alunbrig, Fruzaqla, Ninlaro |
| Genentech, INC. | $236.84 | 2019-2024 | Tecentriq, Phesgo |
| Pharmaessentia USA Corporation | $232.57 | 2022-2025 | Besremi |
| Rigel Pharmaceuticals, INC. | $193.07 | 2019-2024 | Rezlidhia, Tavalisse |
| Blueprint Medicines Corporation | $191.58 | 2020-2024 | Ayvakit |
| Emd Serono, INC. | $181.88 | 2019-2024 | Bavencio |
| Epizyme, INC. | $155.83 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $140.83 | 2019-2023 | Gilotrif |
| Taiho Oncology, INC. | $122.23 | 2019-2025 | |
| Clovis Oncology, INC. | $121.55 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $117.66 | 2019-2025 | |
| Puma Biotechnology, INC. | $113.27 | 2020-2025 | |
| Aveo Pharmaceuticals, INC. | $111.50 | 2022-2025 | Fotivda |
| Boston Scientific Corporation | $107.67 | 2021 | |
| Agios Pharmaceuticals, INC. | $103.14 | 2019-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $94.34 | 2019-2023 | Epkinly, Imbruvica |
| Array Biopharma INC | $90.89 | 2019-2024 | Braftovi, Tukysa, Mektovi |
| Octapharma USA, INC. | $90.33 | 2022-2024 | Panzyga, Octagam Immune Globulin (Human) |
| Karyopharm Therapeutics INC. | $84.85 | 2020-2025 | Xpovio |
| Glaxosmithkline, LLC. | $80.94 | 2020-2025 | Ojjaara |
| Myriad Genetic Laboratories, INC. | $79.17 | 2021-2023 | Precisetumor |
| Dova Pharmaceuticals | $73.61 | 2019-2021 | |
| Springworks Therapeutics, INC. | $70.44 | 2024-2025 | Gomekli, Ogsiveo |
| Janssen Pharmaceuticals, INC | $62.17 | 2019-2025 | Xarelto |
| Deciphera Pharmaceuticals INC. | $61.95 | 2023-2025 | Qinlock |
| Stemline Therapeutics INC. | $61.49 | 2024-2025 | Orserdu |
| Adaptive Biotechnologies Corporation | $58.37 | 2022-2025 | Clonoseq |
| Sobi, INC | $56.78 | 2022-2024 | |
| Novocure INC. | $51.88 | 2019-2023 | Optune |
| G1 Therapeutics, INC. | $51.78 | 2021-2023 | Cosela |
| Kite Pharma, INC. | $51.16 | 2020-2024 | Yescarta |
| Sun Pharmaceutical Industries INC. | $50.30 | 2022-2025 | |
| Jazz Pharmaceuticals INC. | $49.26 | 2021-2024 | |
| Coherus Oncology, INC. | $48.64 | 2022-2024 | |
| Regeneron Healthcare Solutions, INC. | $45.62 | 2023-2025 | Libtayo |
| Tesaro, INC. | $45.12 | 2019 | |
| Iovance Biotherapeutics, INC. | $41.31 | 2025 | Amtagvi |
| Alexion Pharmaceuticals, INC. | $41.12 | 2022-2025 | Ultomiris |
| Cti Biopharma Corp. | $39.45 | 2022-2023 | Vonjo |
| Foundation Medicine, INC. | $37.46 | 2019-2021 | |
| Pharmacosmos Therapeutics INC. | $35.93 | 2024-2025 | Monoferric |
| Tersera Therapeutics LLC | $35.48 | 2024 | Zoladex |
| Beone Medicines USA, INC. | $34.39 | 2025 | Brukinsa |
| Tolmar, INC. | $32.66 | 2023-2025 | Eligard, Rubraca |
| Dendreon Pharmaceuticals LLC | $28.48 | 2019-2021 | |
| Myovant Sciences INC. | $26.68 | 2021-2022 | |
| Amag Pharmaceuticals, INC. | $24.94 | 2020-2022 | |
| Morphosys, US INC. | $24.15 | 2021 | |
| Adc Therapeutics America, INC. | $19.40 | 2023 | |
| Accord Healthcare, INC. | $19.28 | 2025 | |
| Genmab U.S., INC. | $18.92 | 2024 | Epkinly |
| Catalyst Pharmaceuticals, INC. | $18.91 | 2023 | Firdapse |
| Pharmaand Gmbh | $18.69 | 2025 | Rubraca |
| Janssen Scientific Affairs, LLC | $18.21 | 2022 | |
| Fennec Pharmaceuticals, INC. | $17.84 | 2025 | Fyarro |
| Tg Therapeutics, INC. | $16.53 | 2021 | |
| Sumitomo Pharma America, INC. | $15.90 | 2023 | Orgovyx |
| Geron Corporation | $15.90 | 2025 | Rytelo |
| Mirati Therapeutics, INC. | $15.48 | 2023 | Krazati |
| Siemens Medical Solutions USA, INC. | $14.61 | 2024 | Biograph Vision 600 (8 Ring/64 Ct) |
| Kyowa Kirin, INC. | $14.50 | 2024 | Poteligeo |
| Blue Earth Diagnostics | $14.24 | 2024 | |
| Acrotech Biopharma INC. | $13.92 | 2023 | Beleodaq |
| Progenics Pharmaceuticals, INC. | $13.70 | 2025 | |
| Eusa Pharma (US) LLC | $12.42 | 2022 | |
| Verastem, INC. | $11.83 | 2020 | |
| Heron Therapeutics, INC. | $9.49 | 2019 | |
| Organon LLC | $6.91 | 2024 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
Keytruda $407Enhertu $302Carvykti $281Opdivo $237Tecvayli $214Darzalex $192Besremi $189Xtandi $182Tibsovo $167Onivyde $166Reblozyl $163Epkinly $162Imbruvica $152Opdualag $151Jaypirca $145Verzenio $145Tecentriq $142Rybrevant $134Talzenna $132Lenvima $132Padcev $132Kisqali $131Sarclisa $128Jakafi $120Fabhalta $111Pomalyst $110Pluvicto $110Scemblix $102Venclexta $101Lynparza $100Elitek $98.00Orgovyx $97.17Injectafer $95.85Pemazyre $94.48Monjuvi $94.48Talvey $94.29Tukysa $91.28Gazyva $86.99Lunsumio $86.99Inlyta $84.11Fotivda $82.54Idhifa $80.16Adcetris $79.80Calquence $74.55Tivdak $69.19Retevmo $68.82Elrexfio $65.05Qinlock $61.95Orserdu $61.49Columvi $61.41Polivy $61.41Mekinist $61.18Nplate $61.18Vectibix $61.18Xgeva $61.18Voranigo $60.68Lonsurf $60.20Inqovi $60.20Xofigo $59.11Nubeqa $59.11Piqray $58.20Ibrance $57.93Lutathera $57.50Gomekli $57.28Datroway $57.17Trodelvy $56.65Ayvakit $50.02Promacta $47.79Kyprolis $46.42Libtayo $45.62Panzyga $44.01Jevtana $43.96Vonjo $42.32Amtagvi $41.31Elahere $40.29Krazati $39.79Lumakras $39.61Phesgo $38.22Precisetumor $37.44Rubraca $37.38Monoferric $35.93Gilotrif $35.81Odomzo $35.72Yonsa $35.72Zoladex $35.48Alunbrig $35.04Fruzaqla $34.87Brukinsa $34.39Ninlaro $34.09Udenyca $33.98Eligard $32.66Bavencio $32.42Welireg $29.53Stivarga $29.41Vitrakvi $29.41Clonoseq $29.07Cabometyx $28.88Rezlidhia $28.25Tavalisse $28.25Ultomiris $27.95
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Wender listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.